BioMarin trades up to $162M for Repligen's stable of HDAC inhibitors

BioMarin ($BMRN) is taking a flyer on HDAC inhibitors, taking up Repligen's ($RGEN) portfolio in exchange for as much as $162 million and adding candidates in Friedreich's ataxia and other neurological disorders. Under the deal, BioMarin will fork over just $2 million up front with the rest tied to milestones, and Repligen is eligible for an undisclosed cut of any marketable drugs that stem from its HDAC technology. The Waltham, MA, biotech has been selling off its discontinued assets to better focus on its bioprocessing business, last year handing Pfizer ($PFE) a Phase I drug for spinal muscular atrophy in exchange for up to $70 million. Release

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.